lobbying_activities: 3327530
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3327530 | e0df904c-d6d1-4144-8b37-f405d3beb9e3 | Q1 | MEDSECUREAN.COM | 401108536 | INDIAN PHARMACEUTICAL ALLIANCE(FORMERLY INDIAN PHARMACEUTICAL ASSOCIATION) | 2025 | first_quarter | HCR | The Indian Pharmaceutical Alliance (IPA) is dedicated to ensuring a level playing field in the U.S. pharmaceutical market and upholding the principles of the U.S. Hatch-Waxman Act to balance innovation with access. IPA members supply nearly 50% of Medicare Prescriptions, and of the top 10 U.S. therapeutic categories, the companies supply more than half of the prescriptions for 5 of the top 10 categories-ranging up to 60%. IPA members seek to explore U.S. - India supply chain resiliency partnership, and address affordable medicine sustainability reform measures. IPA actively supports targeted reforms to enhance the sustainability of the generic drug industry. Specifically, IPA advocates for substantial reforms of Pharmacy Benefit Managers (PBMs) and Group Purchasing Organizations (GPOs) to ensure transparent pricing and fair market practices that benefit consumers. Additionally, IPA champions efforts to close loopholes in the Hatch-Waxman Act that delay generic drug entry, facilitating timely access to affordable medications. These reforms are crucial for maintaining industry sustainability, reducing healthcare costs, and ensuring that effective, affordable treatment options remain accessible to all Americans. IPAs efforts underscore its pivotal role in promoting a healthy future for all Americans through enhanced access to affordable medicine and a robust, enduring pharmaceutical industry. | Commerce, Dept of (DOC),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),Treasury, Dept of,U.S. Trade Representative (USTR),White House Office | 15000 | 0 | 0 | 2025-03-05T13:43:23-05:00 |